Quarterly report pursuant to Section 13 or 15(d)

STOCK OPTIONS

v3.20.2
STOCK OPTIONS
 9 Months Ended
Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
STOCK OPTIONS

NOTE 14. STOCK OPTIONS

 

On May 10, 2018, the Board ratified and confirmed the 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan is a broad-based plan under which shares of our common stock are authorized for issuance for awards, including stock options, stock appreciation rights, restricted stock, and cash incentive awards to members of our Board, executive officers, employees and independent contractors. As of September 30, 2020, a total of 6,550,750 shares of our common stock were authorized for issuance. As of September 30, 2020, 381,701 shares remained available for issuance as new awards under the 2014 Plan.

 

Stock options. During the nine months ended September 30, 2020 and 2019, we issued 465,000 and 320,000 options to purchase our common stock, respectively, to members of our Board, executive officers, employees and independent contractors. The fair value of all stock options granted for the nine months ended September 30, 2020 and 2019 was determined to be $435,639 and $564,450, respectively, using the Black-Scholes option pricing model with the following assumptions:

 

 

 

Options Issued 2020

 

 

Options Issued 2019

 

Dividend yield

 

 

0

%

 

 

0

%

Expected volatility

 

70.98% - 76.97%

 

 

71.61% - 72.11%

 

Risk free interest rate

 

0.27% - 1.39%

 

 

1.37% - 2.51%

 

Expected life (years)

 

 

5.00

 

 

 

5.00

 

 

On February 21, 2019, we amended the employment agreement between the Company and Todd Cravens, our President and Chief Executive Officer (“Mr. Cravens”). Among other things, this amendment grants Mr. Cravens an option to purchase 150,000 shares of our common stock at an exercise price of $1.90 per share, which vested on August 1, 2020.

On February 17, 2020, we entered into Amendment No. #2 to the employment agreement with Mr. Cravens. Among other things, Amendment No. #2 provides that Mr. Cravens receive a grant of 225,000 options at a strike price of $1.93 and vest as follows: 88,000 shares on July 26, 2021, 87,000 shares on July 26, 2022 and 50,000 shares on July 26, 2023.

 

A summary of stock option activity is as follows:

 

 

 

Common

Stock

Options

 

 

Weighted-

Average

Exercise

Price

 

 

Aggregate

Intrinsic

Value

 

 

Weighted-

Average

Remaining

Contractual

Term (Years)

 

Outstanding – December 31, 2019

 

 

3,175,000

 

 

$

0.92

 

 

$

2,692,025

 

 

 

2.79

 

Issued

 

 

465,000

 

 

 

1.57

 

 

 

—

 

 

 

—

 

Exercised

 

 

(225,000

)

 

 

0.22

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(100,000

)

 

 

1.57

 

 

 

—

 

 

 

—

 

Outstanding – September 30, 2020

 

 

3,315,000

 

 

$

1.04

 

 

$

144,450

 

 

 

2.49

 

Exercisable – September 30, 2020

 

 

2,245,000

 

 

$

0.81

 

 

$

614,750

 

 

 

1.81

 

 

A summary of unvested stock option activity is as follows:

 

 

 

Common

Stock

Options

 

 

Weighted-

Average

Exercise

Price

 

 

Aggregate

Intrinsic

Value

 

 

Weighted-

Average

Remaining

Contractual

Term (Years)

 

Unvested – December 31, 2019

 

 

1,053,333

 

 

$

1.43

 

 

$

357,734

 

 

 

3.92

 

Granted

 

 

465,000

 

 

 

1.57

 

 

 

—

 

 

 

—

 

Vested

 

 

(348,333

)

 

 

1.29

 

 

 

—

 

 

 

—

 

Forfeited

 

 

(100,000

)

 

 

1.57

 

 

 

—

 

 

 

—

 

Unvested – September 30, 2020

 

 

1,070,000

 

 

$

1.52

 

 

$

(470,300

)

 

 

3.92

 

 

As of September 30, 2020, our unrecognized share-based compensation expense associated with the stock options issued was $708,698, which will be amortized over a weighted-average of 2.24 years.